Side N
Bruker’s spatial biology division: NanoString, Canopy and Acuity
Which sources back which section of this article, and what its evidence base looks like.
Which sources back which section
| Section | Sources behind it |
|---|---|
| What happened | Bruker’s release of 9 Oct 2024, its 10-Qs for Q3 2020, Q3 2025 and Q2 2026, its 2025 10-K and its April 2024 exhibit; NanoString’s 8-Ks on the verdict, the bankruptcy and the sale; 10x’s settlement 8-K; SelectScience on Acuity; Bruker’s AGBT 2026 and AACR 2026 releases; the Q2 2026 call transcript. |
| Timeline | The same documents, dated; plus NanoString’s S-1/A and 10-Qs for Q1 and Q3 2023, its December 2023 reduction-in-force 8-K and its UPC appeal release; BioSTL and Bruker’s 2020 release on Canopy; Canopy’s CellScape release; the PhenomeX agreement; 10x’s Q1 2024 10-Q, injunction release and Atera release; Bruker’s AGBT 2025 release; GEN’s 2026 ranking; Zacks on Atera shipments. |
| The argument | NanoString’s Q3 2023 10-Q, its 2022 results release and its verdict 8-K; Bruker’s April 2024 exhibit and Q2 2026 10-Q; 10x’s settlement 8-K, its Q3 2025 10-Q and its injunction release; GEN’s interview of October 2024; the Q1 2026 call transcript. |
| What others add | Bruker’s AGBT 2025, AGBT 2026 and AACR 2026 releases and the Beacon blog; Canopy’s CellScape release; NanoString’s Q1 2023 10-Q; the PhenomeX agreement; Bruker’s 2025 10-K, 10-Qs for Q3 2025 and Q2 2026, and its three 2026 results releases; both call transcripts; 10x’s 2025 10-K and Atera release; GEN’s interview and ranking; Zacks; DeciBio. |
| Conclusion | Bruker’s Q2 2026 10-Q, 2025 10-K and April 2024 exhibit; its AGBT 2026 and AACR 2026 releases; the Q2 2026 call transcript; GEN’s 2026 ranking; the Atera release and Zacks; DeciBio. |
What the evidence base looks like
- 40Sources used on the page
- 21That are regulatory filings or exhibits to them
- 2Read through a reader service after a direct request was refused; the rest read directly
- 21Links approached and refused, or read and not used
| Function | How many | What they are |
|---|---|---|
| Vendor | 32 | The companies themselves: Bruker’s, NanoString’s and 10x’s filings, Bruker’s, Canopy’s, NanoString’s and 10x’s press releases, and a Bruker blog. |
| Reporting | 6 | Trade journalism, two call transcripts and an investment-research summary. |
| Origin | 1 | The founding investor’s own announcement of a sale it was party to. |
| Reference | 1 | A market-research seller’s report page. |
Reliable
Reliable, but with an interestWorth believing and reliableWeak on both, and used with careHonest, but thin
Worth believing